Wesfarmers Centre of Vaccines & Infectious Diseases
What is an adaptive trial?
Team
Infectious Disease Implementation Research projects
Resources
Extra whooping cough shot to protect your bub
Professor Tom Snelling
Reports and Findings
among children with pneumonia using a causal Bayesian network
Pneumonia remains a leading cause of hospitalization and death among young children worldwide, and the diagnostic challenge of differentiating bacterial from non-bacterial pneumonia is the main driver of antibiotic use for treating pneumonia in children. Causal Bayesian networks (BNs) serve as powerful tools for this problem as they provide clear maps of probabilistic relationships between variables and produce results in an explainable way by incorporating both domain expert knowledge and numerical data.
Infectious Disease Implementation Research Infectious Diseases Epidemiology Vaccine Trials Group Subsite: Wesfarmers Centre of Vaccines and Infectious Diseases Bacterial Respiratory Infectious Disease GroupBEAT CF pulmonary exacerbations core protocol for evaluating the management of pulmonary exacerbations in people with cystic fibrosis
Cystic fibrosis (CF) is a rare, inherited, life-limiting condition predominantly affecting the lungs, for which there is no cure. The disease is characterized by recurrent pulmonary exacerbations (PEx), which are thought to drive progressive lung damage. Management of these episodes is complex and generally involves multiple interventions targeting different aspects of disease. The emergence of innovative trials and use of Bayesian statistical methods has created renewed opportunities for studying heterogeneous populations in rare diseases.
Cystic Fibrosis Published research Infectious Disease Implementation Research P4 Respiratory Health for Kids Subsite: Walyan BREATHCore protocol for the adaptive Platform Trial In COVID-19 Vaccine priming and BOOsting (PICOBOO)
The need for coronavirus 2019 (COVID-19) vaccination in different age groups and populations is a subject of great uncertainty and an ongoing global debate. Critical knowledge gaps regarding COVID-19 vaccination include the duration of protection offered by different priming and booster vaccination regimens in different populations, including homologous or heterologous schedules.
Published research Immunisation Infectious Diseases Infectious Disease Implementation Research Infectious Diseases Epidemiology Vaccine Trials Group Subsite: Wesfarmers Centre of Vaccines and Infectious Diseases COVID-19Off-target effects of bacillus Calmette-Guerin vaccination on immune responses to SARS-CoV-2: implications for protection against severe COVID-19
Because of its beneficial off-target effects against non-mycobacterial infectious diseases, bacillus Calmette-Guérin vaccination might be an accessible early intervention to boost protection against novel pathogens. Multiple epidemiological studies and randomised controlled trials are investigating the protective effect of BCG against coronavirus disease 2019 (COVID-19).
Published research Immunisation Human Capability Systems Immunology Infectious Disease Implementation Research Vaccine Trials Group Subsite: Wesfarmers Centre of Vaccines and Infectious Diseases COVID-19 Immune system Strep A & ARF Therapeutics